-
公开(公告)号:WO0204412A3
公开(公告)日:2002-08-22
申请号:PCT/US0141271
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52 , A61K31/165 , A61K31/166
CPC classification number: C07D213/40 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D257/04 , C07D307/52
Abstract: Disclosed are compounds of the Formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R , R , R , R and R are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
Abstract translation: 公开了式(I)化合物及其药学上可接受的盐和前药,其中A,B,R 1,R 2,R 3,R 4和R 5如上所定义 在规范中。 这些化合物是酪氨酸磷酸酶抑制剂,可用于治疗或预防II型糖尿病。 本发明还包括包含所述化合物的制剂,制备这些化合物的方法,治疗或预防II型糖尿病的方法。
-
公开(公告)号:ES2312461T3
公开(公告)日:2009-03-01
申请号:ES01956161
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG
IPC: C07C311/19 , A61K31/165 , A61K31/166 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52
Abstract: Compuesto de la fórmula (Ver fórmula) y sus sales farmacéuticamente aceptables, en la que R 1 se selecciona de entre hidrógeno, hidroxilo, halógeno, amino, monoalquilamino trifluorometilo, aminometilo, ciano, nitro, y heteroarilo opcionalmente sustituido con uno, dos, o tres grupos seleccionados independientemente de entre halógeno, alquilo C1 - 6, hidroxilo, amino, mono- o dialquilamino, trifluorometilo, -C(O)R 8 , -COOR 8 , -C(O)NHR 8 , y -OR 8 ; R 2 se selecciona de entre hidrógeno, hidroxilo, halógeno, alquilo C1 - 6, alcoxi C1 - 6, alcoxialquilo, hidroxialquilo, C2 - 6-alquenilo, amino, mono- o dialquilamino, ciano, nitro, trifluorometilo, -CON(R 6 )2, y arilo y heteroarilo opcionalmente sustituidos con uno, dos, o tres grupos seleccionados independientemente de entre halógeno, alquilo C1 - 6, hidroxilo, amino, mono- o dialquilamino, trifluorometilo, -C(O)R 8 , -COOR 8 , -C(O)NHR 8 , y -OR 8 ; R 3 , R 4 , R 5 se seleccionan independientemente de entre hidrógeno, hidroxilo, halógeno, alquilo C1 - 6, alquenilo C2 - 6, cicloalquilo, ciano, -CON(R 6 )2 y COOR 6 , y arilo y heteroarilo opcionalmente sustituidos con uno, dos o tres grupos seleccionados independientemente de entre halógeno, alquilo C1 - 6, hidroxilo, amino, mono- o dialquilamino, trifluorometilo, -C(O)R 8 , -COOR 8 , -C(O)NHR 8 , y -OR 8 ; A es -S(O)2R 7 ; B se selecciona de entre hidrógeno, alquilo C1 - 6, alquenilo C2 - 6, alquinilo C2 - 6, (CH2)nS(O)qR 7 , -(CH2)pC(O)R 7 , -(CH2)pC(O)NHR 7 , -(CH2)pCO2R 7 , -(CH2)nOR 7 , y arilo, heteroarilo, ariloalquilo, ariloalquelino, ariloalquinilo, heteroarilalquilo, heteroarilalquenilo y heteroarilalquinilo, en los que la porción de anillo de cada uno se sustituye opcionalmente con uno, dos o tres grupos seleccionados independientemente de entre halógeno, alquilo C1 - 6, hidroxilo, amino, mono- o dialquilamino, trifluorometilo, -C (O)R 8 , -COOR 8 , -C(O)NHR 8 , y -OR 8 ; n es...
-
公开(公告)号:AU7818801A
公开(公告)日:2002-01-21
申请号:AU7818801
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52 , A61K31/165 , A61K31/166
Abstract: Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification.Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:CA2416220A1
公开(公告)日:2002-01-17
申请号:CA2416220
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: GAUDINO JOHN , SUN XICHENG , BURGESS LAURENCE E , WALLACE ELI M , GRONEBERG ROBERT D , RODRIGUEZ MARTHA E , NORMAN MARK H
IPC: A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52 , A61K31/165 , A61K31/166
Abstract: Disclosed are compounds of the Formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, R4 and R5 are as defin ed in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds , processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:CA2416220C
公开(公告)日:2010-04-06
申请号:CA2416220
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: C07C311/19 , A61K31/165 , A61K31/166 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52
Abstract: Disclosed are compounds of the Formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, R4 and R5 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:DE60135752D1
公开(公告)日:2008-10-23
申请号:DE60135752
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: C07C311/19 , A61K31/165 , A61K31/166 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52
Abstract: Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification.Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:AU2001278188B2
公开(公告)日:2007-05-17
申请号:AU2001278188
申请日:2001-07-05
Applicant: AMGEN INC , ARRAY BIOPHARMA INC
Inventor: GAUDINO JOHN , RODRIGUEZ MARTHA E , WALLACE ELI M , GRONEBERG ROBERT D , BURGESS LAURENCE E , SUN XICHENG , NORMAN MARK H
IPC: C07C311/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52
Abstract: Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification.Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:AT407923T
公开(公告)日:2008-09-15
申请号:AT01956161
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE , GAUDINO JOHN , GRONEBERG ROBERT , NORMAN MARK , RODRIGUEZ MARTHA , SUN XICHENG , WALLACE ELI
IPC: C07C311/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52
Abstract: Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification.Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:NZ523483A
公开(公告)日:2004-08-27
申请号:NZ52348301
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52 , A61K31/165 , A61K31/166
Abstract: Disclosed are compounds of the formula (I), and pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, R1, R2, R3, R4 and R5 are as defined in the specification. Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also disclosed are formulations comprising these compounds, processes for preparing such compounds and a method for treating or preventing Type II Diabetes Mellitus.
-
公开(公告)号:BR0112216A
公开(公告)日:2004-02-10
申请号:BR0112216
申请日:2001-07-05
Applicant: ARRAY BIOPHARMA INC , AMGEN INC
Inventor: BURGESS LAURENCE E , GAUDINO JOHN , GRONEBERG ROBERT D , NORMAN MARK H , RODRIGUEZ MARTHA E , SUN XICHENG , WALLACE ELI M
IPC: A61K31/192 , A61K31/194 , A61K31/196 , A61K31/341 , A61K31/4045 , A61K31/41 , A61K31/4402 , A61P3/10 , A61P7/12 , A61P35/00 , A61P43/00 , C07C237/22 , C07C311/13 , C07C311/19 , C07C311/29 , C07D209/14 , C07D209/16 , C07D213/40 , C07D257/04 , C07D307/52 , A61K31/165 , A61K31/166
Abstract: Disclosed are compounds of the Formula Iand pharmaceutically acceptable salts and prodrugs thereof, wherein A, B; R1, R2, R3, R4 and R5 are as defined in the specification.Such compounds are tyrosine phosphatase inhibitors and useful in the treatment or prevention of Type II Diabetes Mellitus. Also encompassed by the invention are formulations comprising the noted compounds, processes for preparing such compounds, a method for treating or preventing Type II Diabetes Mellitus.
-
-
-
-
-
-
-
-
-